BRCA2 and triple-negative breast carcinoma: From the 184 patients diagnosed with triple-negative breast cancer, 152 had a negative result, 18 had a pathogenic BRCA1 mutation, four had a pathogenic BRCA2 mutation, two had a VUS mutation in the BRCA1 gene, two had a VUS mutation in the BRCA2 gene, four had the moderate risk variant c.9976A>T (p.Lys3326Ter) in the BRCA2 gene, and two had a large deletion in the BRCA1 gene (Table 1).